- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06945484
Pilot för Precision Posaction Regime for Cancer Care (PERCC) Studie (PILOT PERCC)
This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a pilot study evaluating the feasibility of the Precision Exercise Regimen for Cancer Care (PERCC) intervention in stage II and stage III Non-Small Cell Lung Cancer (NSCLC) patients receiving multimodal therapy at the Huntsman Cancer Institute (HCI) at the University of Utah. Eligible patients will begin the intervention at the pre-treatment clinic visit and continue until approximately two months post-surgery.
The PERCC intervention is a virtually supervised home-based exercise program. Participants will engage in exercise starting at least two weeks before receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment. The exercise modes will include basic transfer and calisthenics mobility, aerobic, and resistance exercises and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting).
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Thomas Varghese, MD, MS, MBA, FACS
- Telefonnummer: 801-581-5311
- E-post: thomas.varghese@hsc.utah.edu
Studera Kontakt Backup
- Namn: Cornelia Ulrich, MS, PhD
- Telefonnummer: 801-213-5716
- E-post: neli.ulrich@hci.utah.edu
Studieorter
-
-
Texas
-
Galveston, Texas, Förenta staterna, 77555
- Rekrytering
- University of Texas Medical Branch at Galveston
-
Kontakt:
- Rebecca Geck, MSN/MPH
- Telefonnummer: 409-266-0496
- E-post: raschaef@utmb.edu
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Rekrytering
- Huntsman Cancer Institute
-
Kontakt:
- Vicky Bandera
- E-post: Vicky.Bandera@hci.utah.edu
-
Huvudutredare:
- Thomas Varghese, MD, MS, MBA, FACS
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Ages 18 and older at time of diagnosis
- Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC)
- Patient receives neoadjuvant therapy (defined as chemotherapy, radiation therapy immunotherapy, or any combination of these modalities) and surgery
- Patient able to follow direction and complete questionnaires in English or Spanish
- Patient agrees to complete the PERCC intervention
Exclusion Criteria:
- Morbidly obese (BMI >40 kg/m2 ) or anorexic (BMI <17.5 kg/m2 )
- Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance
- Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer)
- Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Precision Exercise Regimen for Cancer Care (PERCC)
Participants will engage in PERCC starting at least two weeks prior to receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment. |
PERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Feasibility - Recruitment and Retention
Tidsram: up to two months post-surgery
|
Feasibility of the PERCC intervention will be evaluated by our ability to recruit and retain the needed number of patients with 80% exercise intervention attendance. |
up to two months post-surgery
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Feasibility - Safety
Tidsram: up to two months post-surgery
|
The feasibility of the PERCC intervention will be evaluated based on participant safety. This outcome measure will assess the safety and tolerability of the study treatment. The severity of AEs will be assessed using CTCAE v5.0 criteria, a 1-5 scale with higher numbers indicating greater severity. Grade 1 indicates "mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated" and Grade 5 indicates "death related to AE". Subjects will be monitored for adverse events from the start of treatment until two months post-surgery. |
up to two months post-surgery
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Thomas Varghese, MD, MS, MBA, FACS, Huntsman Cancer Institute
Publikationer och användbara länkar
Allmänna publikationer
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
- Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O'Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020 Nov 4;371:m4087. doi: 10.1136/bmj.m4087.
- Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K; OCN; Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059.
- Tchelebi LT, Shen B, Wang M, Potters L, Herman J, Boffa D, Segel JE, Park HS, Zaorsky NG. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States. Adv Radiat Oncol. 2022 Mar 8;7(5):100938. doi: 10.1016/j.adro.2022.100938. eCollection 2022 Sep-Oct.
- Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Feb;12(2):314-322. doi: 10.1016/j.jtho.2016.09.122. Epub 2016 Oct 5.
- Yalman D. Invited Editorial on "the timing of surgery after neoadjuvant chemoradiation in locally advanced non-small cell lung cancer". J Thorac Dis. 2017 Mar;9(3):E299-E300. doi: 10.21037/jtd.2017.02.98. No abstract available.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 162865
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .